28.10.2021 – 05:30
Medigen Vaccine Biologics Corporation
TAIPEI, June 23 / PRNewswire /
The vaccine candidate MVC-COV1901 from Medigen Vaccine Biologics Corp (MVC) was recommended by an independent advisory group for the prioritization of vaccines for inclusion in the solidarity vaccine trial (STv) of the World Health Organization (WHO). After reviewing around 20 vaccine candidates by the external advisory group, MVC selected the vaccine as one of two to be included in the global study.
the announcement WHO comes after the study has been approved by the WHO Ethics Committee and relevant regulatory and ethics committees of Colombia, Mali and the Philippines. The individual clinical centers and their respective national investigators and research teams have started recruiting volunteers to participate in the study.
It is an international, randomized, clinical trial platform to rapidly evaluate the efficacy and safety of promising new vaccine candidates, with the aim of helping create a larger portfolio of vaccines needed to protect people from Covid-19 around the world.
MVC began developing its own vaccine in February 2020 in hopes of finding a solution that may do some of its part in ending the devastating pandemic. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen, adjuvanted with CpG 1018 from Dynavax and aluminum hydroxide.
“We are very grateful that we were selected to participate in the WHO international solidarity study on vaccines against Covid-19. We have worked to develop a vaccine that has few side effects and actively protects the population from the harmful effects of the virus “With the results so far encouraging, we hope that the international study carried out by WHO and participating countries will help contain the escalation of cases,” said Charles Chen, Vice Chairman & CEO, Medigen Vaccine Biologics Corp.
As the battle against the pandemic continues, the need for effective vaccines remains high and MVC believes it has the capacity, infrastructure and expertise to help protect global protection.
Information on MVC-COV1901
MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen that is produced with CpG 1018 from Dynavax and aluminum hydroxide is adjuvanted. The S-2P antigen is a trimeric and prefusion-stable recombinant spike protein produced by the US NIH was developed. MVC has received a global technology license for S-2P from the US Vaccine Research Center of the National Institutes of Health (NIH). Building on the S-2P platform, MVC carried out large-scale screenings of various adjuvants and finalized the compositions of the vaccine MVC-COV1901 to optimize safety and the desired immunogenicity properties. MVC built the production platform for MVC-COV1901 and demonstrated robust safety and promising immunogenicity based on data from preclinical, Phase I and Phase II clinical studies. As a result, MVC-COV1901 has applied for and received the EUA in Taiwan and continues to seek worldwide approval.
About Medigen Vaccine Biologics Corp. (MVC)
MVC is a biopharmaceutical company that uses cell-based technologies to develop new vaccines and biosimilars. With the goal of national self-sufficiency, MVC also wants to provide vaccines and biopharmaceuticals to meet regional needs and to help against the threat of infectious diseases worldwide. MVC’s pipeline includes a vaccine against the enterovirus EV71, a dengue vaccine and a tetravalent influenza vaccine, all of which are in late-stage clinical trials. MVC’s large-scale production facility is state-of-the-art and complies with international PIC / s GMP requirements. For more information, see www.medigenvac.com.
WHO media inquiries
Medigen Kontakt: Paul Torkehagen Direktor, Internationale Geschäftsentwicklung [email protected]
Medigen media inquiries:
Michelle Bridget, Continuum PR, on +6 012 697 7356 or email [email protected]
Original content by: Medigen Vaccine Biologics Corporation, transmitted by news aktuell